These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15083480)

  • 21. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
    Sucharew H; Goss CH; Millard SP; Ramsey BW;
    Contemp Clin Trials; 2006 Dec; 27(6):561-70. PubMed ID: 16875884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How important is exact balance in treatment and control sample sizes to evaluations?
    Elliott MN; McCaffrey DF; Lockwood JR
    J Subst Abuse Treat; 2007 Jul; 33(1):107-10. PubMed ID: 17376636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
    Licciardone JC; Russo DP
    J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population.
    Plummer M; Vivas J; Lopez G; Bravo JC; Peraza S; Carillo E; Cano E; Castro D; Andrade O; Sánchez V; Garcia R; Buiatti E; Aebischer C; Franceschi S; Oliver W; Muñoz N
    J Natl Cancer Inst; 2007 Jan; 99(2):137-46. PubMed ID: 17227997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical trial of patient satisfaction and prosthodontic needs with ball and bar attachments for implant-retained complete overdentures: three-year results.
    MacEntee MI; Walton JN; Glick N
    J Prosthet Dent; 2005 Jan; 93(1):28-37. PubMed ID: 15623995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling motor vehicle crashes using Poisson-gamma models: examining the effects of low sample mean values and small sample size on the estimation of the fixed dispersion parameter.
    Lord D
    Accid Anal Prev; 2006 Jul; 38(4):751-66. PubMed ID: 16545328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure.
    Srivastava DK; Rai SN; Pan J
    Biom J; 2007 Jun; 49(3):351-64. PubMed ID: 17623341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods for modelling change in cluster randomization trials.
    Klar N; Darlington G
    Stat Med; 2004 Aug; 23(15):2341-57. PubMed ID: 15273952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and analysis of trials with rare outcomes: examples from trials in herpes transmission and influenza prophylaxis.
    Keene O
    Contemp Clin Trials; 2005 Jun; 26(3):311-22. PubMed ID: 15911465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.
    Mielke M; Munk A; Schacht A
    Stat Med; 2008 Nov; 27(25):5093-110. PubMed ID: 18570271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size calculations for 3-level cluster randomized trials.
    Teerenstra S; Moerbeek M; van Achterberg T; Pelzer BJ; Borm GF
    Clin Trials; 2008; 5(5):486-95. PubMed ID: 18827041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
    Nie L; Chu H; Cole SR
    Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.
    Lu Q; Tse SK; Chow SC; Lin M
    J Biopharm Stat; 2012; 22(4):773-84. PubMed ID: 22651114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A procedure for group sequential comparative poisson trials.
    Xia Q; Hoover DR
    J Biopharm Stat; 2007; 17(5):869-81. PubMed ID: 17885871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculation based on efficient unconditional tests for clinical trials with historical controls.
    Shan G; Moonie S; Shen J
    J Biopharm Stat; 2016; 26(2):240-9. PubMed ID: 25551261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing whether an identified treatment is best.
    Laska EM; Meisner MJ
    Biometrics; 1989 Dec; 45(4):1139-51. PubMed ID: 2611321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economizing comparative Poisson clinical trials of multiple experimental treatments by testing against the same control.
    Chiarappa JA; Hoover DR; Pedley A
    Stat Methods Med Res; 2023 Aug; 32(8):1604-1615. PubMed ID: 37386823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.